...
【24h】

Successful Use of Rituximab in Refractory Idiopathic Thrombocytopenic Purpura in a Patient With Common Variable Immunodeficiency

机译:利妥昔单抗在难治性特发性血小板减少性紫癜患者中的成功应用

获取原文

摘要

Idiopathic thrombocytopenic purpura (ITP) is a common autoimmune disease in patients with common variable immunodeficiency (CVID). We describe a 36-year-old woman with CVID. The clinical course of her disease was complicated by bronchiectasis, antiphospholipid antibody syndrome, and portal vein thrombosis. She developed recurrent attacks of ITP refractory to high doses of corticosteroid, intravenousimmunoglobulin (IVIG), and splenectomy. She received a total of 5 doses of rituximab (375 mg/m2) and achieved an immediate and persistent response. Therapy was well tolerated. Her platelet count remained above 370 000/μL for 8 months of follow-up, despite repeated infections. During this period the patient remained off corticosteroids and on continuous IVIG replacement therapy.Key words: Rituximab. Idiopathic thrombocytopenic purpura. Common variable immunodeficiency.
机译:特发性血小板减少性紫癜(ITP)是具有常见可变免疫缺陷(CVID)的患者的常见自身免疫性疾病。我们描述了一名CVID的36岁女性。她的疾病的临床过程因支气管扩张,抗磷脂抗体综合征和门静脉血栓形成而并发。她发生了对大剂量皮质类固醇,静脉内免疫球蛋白(IVIG)和脾切除术难治的ITP复发发作。她总共接受了5剂量的利妥昔单抗(375 mg / m2),并获得了即时和持续的反应。治疗耐受性好。尽管反复感染,但在随访的8个月中,她的血小板计数仍保持在370 000 /μL以上。在此期间,患者不再使用皮质类固醇,并继续进行IVIG替代治疗。关键词:利妥昔单抗。特发性血小板减少性紫癜。常见的可变免疫缺陷。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号